

WHO Expert Committee on Biological Standardization

Seventy-first report



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; order on line: www.who.int/bookorders).

W H O T e c h n i c a l R e p o r t S e r i e s
1 0 2 8

WHO Expert Committee on Biological Standardization

Seventy-first report

*This report contains the views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health
Organization**

WHO Expert Committee on Biological Standardization: seventy-first report

(WHO Technical Report Series, No. 1028)

ISBN 978-92-4-002014-6 (electronic version)

ISBN 978-92-4-002015-3 (print version)

ISSN 0512-3054

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO Expert Committee on Biological Standardization: seventy-first report. Geneva: World Health Organization; 2021 (WHO Technical Report Series, No. 1028). Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Contents

Abbreviations	xi
1. Introduction	1
2. Strategic directions in biological standardization: impact of COVID-19	3
2.1 WHO collaborations and partnerships related to COVID-19	3
2.1.1 Overview of the WHO response to COVID-19	3
2.1.2 Update from the R&D Blueprint	4
2.1.3 Priorities of the Coalition for Epidemic Preparedness Innovations	5
2.2 WHO COVID-19 vaccine-related activities	7
2.2.1 Overview from WHO	7
2.2.2 Development of a WHO guidance document on regulatory considerations in the evaluation of mRNA vaccines	9
2.2.3 A need for standardization	10
2.2.4 Proposal from the WHO Pharmacovigilance secretariat	12
2.3 WHO COVID-19 blood-related activities	13
2.3.1 Overview from WHO	13
2.3.2 WHO interim guidance on maintaining a safe and adequate blood supply during the COVID-19 pandemic and on the collection of CCP	14
3. International Recommendations, Guidelines and other matters related to the manufacture, quality control and evaluation of biological products	16
3.1 Biotherapeutics other than blood products	16
3.1.1 Second WHO International Standard for serum gonadotrophin (equine)	16
3.2 Vaccines and related substances	17
3.2.1 Guidelines on the quality, safety and efficacy of plasmid DNA vaccines	17
3.2.2 Amendment to the WHO Guidelines for the safe production and quality control of poliomyelitis vaccines	19
3.2.3 Revision of the WHO Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines	20
4. International reference materials – blood products and related substances	22
4.1 WHO international reference standards for blood products and related substances	22
4.1.1 Third WHO International Standard for thrombin	22
5. International reference materials – in vitro diagnostics	24
5.1 WHO international reference standards for in vitro diagnostics	24
5.1.1 First WHO International Standard for <i>Plasmodium vivax</i> antigen	24
6. International reference materials – standards for use in high-throughput sequencing technologies	26
6.1 Proposed new projects and updates – standards for use in high-throughput sequencing technologies	26

6.1.1	Proposed First WHO International Reference Panel A for adventitious virus detection by high-throughput sequencing	26
6.1.2	Proposed WHO international reference reagents for adventitious virus detection by high-throughput sequencing	27
7.	International reference materials – standards for use in public health emergencies	29
7.1	Proposed new projects and updates – standards for use in public health emergencies	29
7.1.1	Proposed First WHO International Standard for SARS-CoV-2 RNA for NAT-based assays	29
7.1.2	Proposed First WHO International Standard for anti-SARS-CoV-2 immunoglobulin	30
8.	International reference materials – vaccines and related substances	32
8.1	WHO international reference standards for vaccines and related substances	32
8.1.1	WHO International Reference Reagent for anti-malaria (<i>Plasmodium vivax</i>) plasma (human)	32
Annex 1		
	WHO Recommendations, Guidelines and other documents related to the manufacture, quality control and evaluation of biological products	35
Annex 2		
	Guidelines on the quality, safety and efficacy of plasmid DNA vaccines	
	Replacement of Annex 1 of WHO Technical Report Series, No. 941	41
Annex 3		
	Guidelines for the safe production and quality control of poliomyelitis vaccines	
	Amendment to Annex 4 of WHO Technical Report Series, No. 1016	95
Annex 4		
	New and replacement WHO international reference standards for biological products	101

WHO Expert Committee on Biological Standardization

Meeting held via WebEx video conferencing on 24 to 28 August 2020

Committee members¹

Dr C. Burns, National Institute for Biological Standards and Control, Potters Bar, the United Kingdom

Professor K. Cichutek, Paul-Ehrlich-Institut, Langen, Germany (*Chair*)

Dr M. Darko, Food and Drugs Authority, Accra, Ghana

Dr I. Feavers, Consultant, Nacton, the United Kingdom (*Rapporteur*)

Dr S. Hindawi, Blood Transfusion Services, Jeddah, Saudi Arabia

Mrs T. Jivapaisarnpong, Advisor, Bangkok, Thailand

Dr H. Klein, National Institutes of Health, Bethesda, MD, United States of America (the USA) (*Vice-Chair*)

Ms C. Morris, National Institute for Biological Standards and Control, Potters Bar, the United Kingdom

Mr V.R. Reddy, South African National Blood Service, Weltevreden Park, South Africa

Dr P. Strengers, Sanquin, Amsterdam, Netherlands

Dr Y. Sohn, Seoul National University, Seoul, Republic of Korea

Dr D. Teo, Health Sciences Authority, Singapore, Singapore

Dr J. Wang, National Institutes for Food and Drug Control, Beijing, China

Dr Y. Wang, National Institutes for Food and Drug Control, Beijing, China

Dr C. Witten, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, the USA

Temporary Advisers²

Ms A. Bonhomme,³ Public Health Agency of Canada, Ottawa, Canada

¹ The decisions of the Committee were taken in closed session with only members of the Committee present. Each Committee member had completed a Declaration of Interests form prior to the meeting. These were assessed by the WHO Secretariat and no declared interests were considered to be in conflict with full meeting participation.

² Temporary advisers include representatives of the drafting groups of the WHO written standards submitted to the Committee for adoption, other subject matter experts and the Editor of the report of the Committee which is published each year in the WHO Technical Report Series.

³ Unable to attend.

- Dr K. Chumakov, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, the USA
- Dr A. Khan, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, the USA
- Dr M.A. Liu, ProTherImmune & Foreign Adjunct Professor, Karolinska Institutet, Stockholm, Sweden
- Dr J. Martin, National Institute for Biological Standards and Control, Potters Bar, the United Kingdom
- Dr G. Mattiuzzo, National Institute for Biological Standards and Control, Potters Bar, the United Kingdom
- Dr E. Mee, National Institute for Biological Standards and Control, Potters Bar, the United Kingdom
- Dr H. Meyer, Paul-Ehrlich-Institut, Langen, Germany
- Dr P. Minor, St Albans, the United Kingdom
- Dr E. Nkansah, Food and Drugs Authority, Accra, Ghana
- Dr K. Peden, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, the USA
- Dr R. Sheets, Grimalkin Partners, Silver Spring, MD, the USA
- Dr A.L. Waddell, Stanley, the United Kingdom (*Editor of the report of the Committee*)
- Dr T. Wu, Biologic and Radiopharmaceutical Drugs Directorate, Health Canada, Ottawa, Canada
- Dr M. Xu, National Institutes for Food and Drug Control, Beijing, China

State actors

- Dr N. Almond, National Institute for Biological Standards and Control, Potters Bar, the United Kingdom

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>